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Abstract 
Background and aims: Infliximab (IFX) and iron sucrose (FeS) are of high value in inflammatory bowel disease 
(IBD). We aimed to assess the relative role of both therapies in IBD related anaemia and their safety when used 
in combination. Methods: IBD patients with anaemia receiving a first series of FeS infusions in addition to IFX 
were prospectively followed. We investigated serum kinetics of erythropoietin (EPO), soluble transferrin 
receptors (sTFRs) and vascular endothelial growth factor (VEGF). Results: Data analysis included 87 patients of 
whom 49.4% achieved the target Hb level of 12.0 g/dL. IFX resulted in a significant increase of EPO and sTFR 
compared to baseline pre-IFX levels (p=0.029 and p=0.005 respectively) and after a 12-week combined FeS and 
IFX treatment, EPO and sTFR levels dropped significantly compared to pre-FeS levels (p<0.001 for both). 
Infusion related adverse events were recorded in 2 IFX treated patients (2.3%, 0.7% of the infusions) and were 
mild. Disease activity and quality of life were not affected. Conclusions: In anaemic IBD patients treated with 
IFX, combined administration of FeS is safe. Infliximab significantly increases serum EPO and sTFR levels 
resulting in an increased functional iron deficiency, which is restored after combined treatment with I.V. iron 
sucrose. 
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1. Introduction 
Intravenous (I.V.) iron treatment is indicated for absolute and functional iron deficiency.1 However, concerns 
have been raised with regards to the long-term and short-term safety of I.V. iron administered as iron dextrane, 
since it has been demonstrated that up to 26% of patients may develop an immediate or delayed reaction to this 
form of I.V. iron.2 These reactions may be anaphylactoid with malaise, itching, urticaria, sweating, myalgia, 
arthralgia and febrile episodes, or even anaphylactic with dyspnoea, hypotension and circulatory collapse.3,4 Few 
if any data indicate that I.V. iron is associated with an increased risk of infections, cardiovascular disease, 
malignancy, or iron overload.35 
Intravenous (I.V.) iron sucrose [FeS] has been used for fifty years and is generally referred to as iron saccharate 
or ferric saccharate. In the remainder of this manuscript the term 'I. V. iron sucrose (FeS)' solely refers to the 
product called Venofer (Venofer®, Vifor Inc., Switzerland).6 The efficacy and safety of FeS has been initially 
demonstrated in patients with end stage renal disease indicating good safety and an efficacy profile which was 
paralleled by improvement in the quality of life.7 
The anti-TNF antibody, Infliximab (IFX) has become a cornerstone immunomodulatory treatment in 
inflammatory bowel disease (IBD) for several indications.8-10 IFX induces healing of mucosal ulcers11 which 
could reduce intestinal iron loss and subsequently alleviate iron deficiency related anaemia (IDRA). 
Recently, there have been reports on increased serum erythropoietin (EPO) levels in IBD patients compared to 
the healthy population.12-14 In contrast, it has been shown that in anaemic IBD patients EPO production is 
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inadequate in relation to the degree of anemia.15-17 
In IDRA, the combination of soluble transferrin receptors (sTFRs) with serum ferritin allows a reliable 
assessment of the iron deficit.18,19 However, in chronic inflammatory conditions such as Crohn's disease, ferritin 
measurement is not always a reliable index. Thus, sTFR levels provide valuable information since they are 
determined by cellular iron demands and erythroid proliferation rate.20 
The VEGF (vascular endothelial growth factor) family and its receptors determine development and homeostasis 
of many organs, including the haematopoietic system, independent of their vascular role. We have previously 
shown that patients with gastrointestinal inflammatory conditions including IBD have significantly increased 
serum VEGF levels compared to healthy subjects.21 
No studies so far have assessed the safety and the effect on haematopoiesis and iron stores of combined FeS and 
IFX treatment in anaemic IBD patients. 
In this study we prospectively assessed the safety of combined IFX and FeS treatment and we investigated the 
serum kinetics of EPO, sTFRs and VEGF during combined therapy with IFX and FeS in a well defined cohort of 
IBD patients with iron deficiency anaemia. 
2. Materials and methods 
2.1. Study design 
We conducted a prospective chart analysis of all IBD anaemic patients on IFX who received FeS during the 
period 2001-2004. All patients received consecutive FeS infusions to achieve a pre-calculated total dose. To 
avoid iron overload infusions were interrupted when the transferrin saturation exceeded 50%. The analysis was 
designed to assess all relevant to the treatment safety issues, to record any adverse event and to demonstrate any 
possible predicting factor(s) for this event. 
In addition we prospectively investigated serum haematopoietic factors kinetics in 29 anaemic CD patients (19 
females) on IFX induction and subsequent systematic treatment (5 mg/kg) who had also received combined FeS 
treatment. Data were stored in and retrieved from hospital electronic records containing all medical and 
laboratory data. Adverse events were specifically captured in the electronic records. 
2.2. Inclusion criteria and exclusion criteria 
Patients diagnosed with iron deficiency IBD-related anaemia, not administered oral iron agents for at least 2 
weeks or with documented poor tolerance or un responsiveness to oral supplementation by iron salts, with 
below-target range of Hb levels (<12 g/dL) and evidence of iron deficiency (Tsat<20%) were included in the 
study population. The minimum follow up time after FeS was set at four months. 
Patients with recent severe bacterial or viral infection, anaemia of other causes (e.g. vitamin B12 deficiency, 
folic acid deficiency, haemolytic disorder, haemoglobinopathy), anticipated need for blood transfusion, asthma, 
eczema or other atopic allergy, history of drug allergy, history of previous allergic reaction to iron, pregnancy, 
severe cardiac, severe hepatic or renal or psychiatric disorders, and any evidence of iron overload (Tsat>50% or 
ferritin>800 ng/ml) were excluded. Patients receiving antihistamines or exogenous erythropoietin were also 
excluded. 
2.3.  I.V. iron sucrose protocol of administration 
The cumulative dose per FeS treatment cycle was calculated using the formula: total iron deficit (mg) = W[kg] × 
[target Hb -actual Hb]g/l × 0.24 + depot iron (500 mg) [W = weight, Hb = haemoglobin].22 FeS was 
administered on a day care basis with consecutive infusions spaced over several weeks to achieve the calculated 
dose. After achieving the precalculated dose and when transferrin saturation exceeded 50% FeS infusions were 
interrupted in order to avoid iron overload. A new FeS cycle was restarted when saturation decreased to less than 
30%.23 
Patients who were scheduled to receive IFX treatment on the same day as FeS received the IFX infusion first, 
followed by a wash out with 50 ml of normal saline and finally FeS was administered using the same venous 
access with a maximal infusion rate of 4 mg/min. 
Prior to the initiation of the first FeS infusion ever each patient received a test dose of 25 mg I.V. FeS over 15 
min titrated with an infusion pump followed by monitoring of vital signs for one hour. Blood analysis was 
always performed before the initiation of IFX and/or FeS infusion. 
2.4.  Safety 
All adverse events at the infusion unit were prospectively recorded. Additional minor or major adverse events 
were reviewed in all patients at each infusion session by physical examination and direct inquiry of patients. 
Published in: Journal of Crohn’s and Colitis (2007), vol. 1, pp. 97-105. 
Status: Postprint (Author’s version) 
 
 
In detail, hypotension was recorded as adverse event if, in the opinion of the attending physician, a decrease in 
blood pressure regardless of degree or absolute value was clinically significant. In case of allergic reaction the 
administration of FeS was interrupted and antihistamines combined with 100 mg of hydrocortisone were I.V. 
administered. 
2.5.  Data analysis 
In addition to demographic data and clinical disease characteristics we recorded the total number of FeS 
infusions, the timing of parallel administration of FeS and IFX, as well as the mean number of infusions per 
patient. 
Haematological parameters such as Hb, transferrin, Tsat, ferritin, were assessed prior to first FeS infusion (pre-), 
after the end of the cycle of infusions (post-), while changes between post- and pre-infusion values were also 
calculated. We also recorded the percentage of patients with Hb>12 g/ dL on the four-month of follow up after 
iron supplementation. To examine possible non-haematopoietic effects of FeS we also determined CRP as well 
as routine serum biochemical parameters before the first infusion and during follow up. 
In addition, Crohn's Disease Activity Index (CDAI) and quality of life assessment as measured by Inflammatory 
Bowel Disease Questionnaire (IBDQ), prior to first FeS infusion and after every FeS infusion cycle was 
retrieved from our prospective IBD database. 
2.6. Kinetics of erythropoietin, VEGF and soluble transferrin receptors 
We performed a prospective kinetic study of serum EPO, sTFR and VEGF levels before and after IFX 
introduction and during combined IFX systematic and FeS infusions according to a predefined schedule (Fig. 1). 
Serum samples were available before introduction of IFX (baseline sample 1), before the initiation of the first 
FeS infusion (sample 2, week 0) and on week 4 (sample 3) and week 12 (sample 4) of FeS treatment. To 
correlate baseline endogenous EPO production to the actual degree of anaemia (Hb levels), we defined expected 
EPO levels based on the degree of anaemia as previously reported (Log EPO = 3.48-0.20X Hb)14 and we 
calculated the ratio of observed vs. expected EPO for each patient separately. We also defined the relative 
increase of EPO (or sTFR) between time points 1 and 2 as the ratio (EP02 - EP01 ) I EP01. 
EPO was measured with EPO-Trac 125l RIA (Diasorin, Saluggia, Italy) and sTFRs were determined with 
Quantikine™ IVD™ ELISA. Reference values for EPO were 8-230 mU/mL and for sTFR 18.4 nmol/l (2.5-97.5 
percentiles: 8.7-28.1 nmol/l ). For EPO the interassay precision is <6% at a level of 160 mU/ml and <15% at 14 
mU/ml and for sTFR the interassay precision of the method is <10%. 
VEGF levels were determined with a specific ELISA (R&D systems, Minneapolis MN) designed to measure the 
most predominant VEGF165 isoform with an intra-assay and the inter-assay precision (coefficient of variation) of 
5.1% and 7.0% respectively. 
2.7.  Ethical considerations 
All patients gave written informed consent for data collection in the IBD database (VLECC study). 
2.8.  Statistical analysis 
Normally distributed continuous variables were described as means±SD and comparisons between pre-post-FeS 
groups were performed using a paired sample T-test. For variables which were not normally distributed we 
performed Mann-Whitney test and Wilcoxon Signed Rank test, and we used the median values expressed with 
the interquartile range (IQR). 
X2 analysis was used when comparing frequencies. For correlation, the Spearman Rank correlation was used.      
A p-value <0.05 (two-tailed) was considered to be significant. Statistical analysis was conducted using the SPPS 
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Figure 1 : Time schedule of serum sampling for the serum EPO, sTFR and VEGF kinetics study during 





3.1. Study population 
Eighty-seven patients [72 Crohn's disease (CD), 15 ulcerative colitis (UC)] were included, of whom 42 patients 
on systematic and 45 patients on episodic IFX treatment (Table 1). In these 87 patients, FeS was scheduled on 
the same day (dose 200-400 mg), immediately after IFX infusion in 37 patients (23 patients in IFX systematic, 
14 patients in episodic use). In 24 patients (10 in IFX systematic, 14 in IFX episodic) the time interval between 
the last IFX dose to the first FeS dose was less than 12 weeks and in 26 patients (9 in IFX systematic and 17 in 
IFX episodic) the last IFX dose to the first FeS dose was exceeding the time interval of 12 weeks. Twenty-two 
(52.4%) IFX systematic patients and 21 (46.7%) IFX episodic patients reached haemoglobin levels > 12 g/dl at 
the end of I.V. iron sucrose infusions. 
Iron store kinetics and haematopoietic parameters were followed in 29/87 patients who initially received IFX 
induction and then were on every 8-week systematic therapy (Table 1). In this group the time interval between 
the last IFX dose to the first FeS dose was less than 12 weeks. 
 
Table 1     Demographics and clinical characteristics of IBD patients on combined infliximab (IFX) and I.V. iron 
sucrose (FeS) treatment 
IFX groups                              Sex (M/F) Age (years ± SD) IBD diagnosisa (CD/UC) Immunosuppressantb 
All IFX (n = 87)                          28/59 35.7 ± 11.5 72/15 77/87 (88.5%) 
IFX-systematic (n = 42)              12/30 34.2 ± 10.2 40/2 42/42 (100%) 
IFX-episodic (n = 45)                  16/29 37.2 ± 12.4 32/13 35/45 (77.8%) 
Kinetics study groupc   N = 29 
Sex (M/F)   10/19 
Age in years (median-IQR)d   26.2 (15.8-49.7) 
Time (months) on IFX before FeS [median, range]  11 (0-50.4) 
Concomitant azathioprine   20/29 
Clinical response to IFX   21/29 (72%) 
Patients with haemoglobin ≥ 12 g/dl after I.V. iron sucrose  23/29 (79%) 
Expected endogenous EPO (mU/mL) [median, range]  19.5 [3.1-63] 
a  CD = Crohn's disease, UC = Ulcerative colitis. 
b  Azathioprine or methotrexate. 
c  Patients with Crohn's disease on IFX systematic therapy 5 mg/kg every 8 weeks. 
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3.2. Efficacy of combined IFX and FeS therapy 
In the whole group a total of 270 FeS infusions were administered (Table 2). A trend towards more patients on 
episodic IFX needing a new FeS cycle (68.9%) compared to IFX systematic (57.1%) was observed (p = 0.07). 
Minimal and maximal daily I.V. iron sucrose dose did not differ between IFX episodic and systematic patients. 
Serum iron-related parameters did not differ between the systematic and episodic IFX systematic group. Also, 
the median (IQR) cumulative FeS dose required to replenish stores was similar in the episodic and systematic 
IFX group (600 [200-1000] mg vs. 600 [400-1000] mg, p = 0.36). 
3.3. Kinetics of erythropoietin, soluble transferrin receptors and VEGF 
The results of the serum kinetic study are presented in Table 3. Baseline observed EPO levels [EPO(1)] were 
significantly higher than expected for the actual degree of anaemia (p = 0.029) and the ratio of observed 
EPO/expected EPO before the initiation of FeS treatment was 1.3 (range 0.4-10.1). We found no correlation 
between the EP01 levels and the ratio of observed EPO/expected EPO with the corresponding CRP and CDAI 
values. 
IFX resulted in a significant increase of EPO(2) and sTFR(2) levels, compared to baseline EPO(1 ) and sTFR(1 ) 
levels with a median (IQR) EPO and sTFR increase of 5.0 (0.0-20.0) mU/mL and 5.2 (0.8-22.9) nmol/l [p = 
0.029 and p = 0.005 respectively] (Figs. 2 and 3). 
After a 12-week period of combined FeS and IFX treatment, EPO(4) and sTFR(4) levels dropped significantly 
compared to the pre-FeS EPO(2) and sTFR(2) levels (p<0.001). Overall, the decrease in EPO levels after the 
initiation of FeS treatment was [median, range] -10.0 mU/mL [-20.0-0.5] and the corresponding decrease in 
sTFR levels was -7.1 nmol/l [-14.2--4.3]. Both EPO and sTFR drops were below baseline levels, although not 
significantly different (Figs. 2 and 3). 
 
Table 2 :  Safety and efficacy of combined I.V. iron sucrose and Infliximab treatment 
Safety and efficacy parameters of combined FeS and IFX treatment Infliximab 
systematic 
(n = 42) 
Infliximab 
episodic 
(n = 45) 
All Infliximab 
patients 
(n = 87) 
No. of patients receiving I.V. iron sucrose immediately after 
Infliximab infusion 
23 14 37 
No. of patients receiving I.V. iron sucrose <12 weeks after 
Infliximab infusion 
10 14 24 
Cumulative number of I.V. iron sucrose infusions 129 141 270 
Number of I.V. iron sucrose infusions per patient (mean ± SD) 3.07 ± 0.31 3.13 ± 1.22 2.78 ± 0.89 
I.V. iron sucrose dose per patient (median with ⁄ IQR) 600 [200-1000] 600 [400-1000] 600 [400-1000] 
Range (min-max) of I.V. iron sucrose dose (Fe3+ mg) per infusion 200-400 200-400 200-400 
No of patients (%) with haemoglobin >12 g/dl at the end of I.V. 
iron sucrose infusions 
22 (52.4%) 21 (46.7%) 43 (49.4%) 
No. of patients (%) needing new cycle of I.V. iron sucrose during 
follow up 
24 (57.1%) 31 (68.9%) 55 (63.2%) 
Short term adverse events (allergic reactions) 0 2 (4.4%) 2 (2.3%) 
Long term adverse eventsa 0 1 (2.2%) 1 (1.1%) 
CRP de novo increasing 12 (28.6%) 13 (28.9%) 25 (28.7%) 
CRP remaining negative or decreasing 30 (71.4%) 32 (71.1%) 62 (71.3%) 
a Low respiratory tract infection (probable). 
 
Table 3 : Kinetics of serum erythropoietin (EPO), vascular endothelial growth factor (VEGF) and soluble 
transferrin receptors (sTFR) in patients with Crohn's disease before and after Infliximab and during a 12-week 
combined I.V. iron sucrose administration 
 Before IFX Before FeS p-value* After FeS p-value** 
EPO (mU/mL) 24.5 (14.5-38.3) 29.0 (19.0-53.0) 0.029 20.0 (14.5-33.5) <0.001 
sTFR (nmol/L) 24.1 (16.9-34.8) 29.7 (20.5-41.7) 0.002 18.8 (14.5-27.7) <0.001 
VEGF (pg/ml) 191 (114-304) 192 (100-318) NS 204 (73-259) NS 
Values are expressed as median (interquartile range). p-value*=comparison of values before IFX and before FeS. p-value**=comparison of 
values before and after FeS. 
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Figure 2 Serum erythropoietin levels in Crohn's disease patients before Infliximab, after Infliximab, before I.V. 
iron sucrose and at 12 weeks of I.V. iron sucrose treatment. 
 
 
Figure 3 Serum soluble transferrin receptor levels in Crohn's disease patients before Infliximab, after 
Infliximab, before I.V. iron sucrose and at 12 weeks of I.V. iron sucrose treatment. 
 
 
The relative (%) decrease in sTFR during combined FeS and IFX treatment correlated with the total dose (mg) of 
FeS [r = -0.705, p<0.001] and the increase in Hb [r = -0.524, p = 0.004], whereas no significant correlation was 
noticed between the relative (%) decrease in EPO levels and the Hb increase [r = -0.294, p = 0.136]. 
EPO increase after the initiation of IFX treatment was significantly higher in the male group of patients 
compared to their female counterparts (p = 0.031). By contrast, after combined FeS and IFX treatment the 
relative change in EPO levels was more pronounced in females (p = 0.023). No significant differences in EPO 
and sTFR levels were noticed between IFX responders and non-responders. 
No significant changes in VEGF levels were noted during IFX or combined FeS therapy and no significant 
correlation at any point of time was observed between VEGF levels and the levels of EPO, sTFRs and 
haemoglobin. 
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3.4. Adverse events 
Subsequent IFX and FeS treatment in one infusion session was well tolerated. The total time of the infusion 
procedure (median time in the hospital for FeS I.V. only 120 min, range 90-240) was acceptable by the great 
majority of the patients. In none of the IFX-treated patients an early or late adverse reaction to IFX had ever been 
recorded previously and none of these patients had ever been receiving any kind of special pre-medication prior 
to each IFX infusion. 
No adverse reaction occurred during I.V. iron sucrose 25-mg test dose. Adverse events considered possibly or 
probably related to I.V. iron sucrose administration were recorded in 2 female patients [2.3% of patients, 0.7% of 
infusions] both on IFX episodic therapy. In detail, one patient had nausea and skin rash during a 200 mg infusion 
and the other patient developed diffuse urticaria during a 400 mg infusion. In the first case infusion was not 
interrupted while in the second case the infusion was truncated at 300 mg. 
One patient was hospitalized two weeks after the end of a FeS cycle with an episode of fever and dyspnoea and a 
differential diagnosis of a lower respiratory tract infection or delayed hypersensitivity to episodic IFX. The 
patient was treated with antibiotics only and discharged few days later in excellent condition. No other patient in 
this cohort reported late adverse events during the 4-month follow up. 
De novo CRP increase between post- and pre-FeS infusion time points occurred in 25 out of 87 patients (28.7%) 
while in the remaining 62 patients (71.3%) CRP remained negative or even decreased during FeS. 
We recorded no cases of bacterial infection and no septicaemia cases related to infection via indwelling 
catheters. CDAI and IBDQ scores were available for patients via the prospective IFX infusion program database. 
No significant changes in disease activity [CDAI (-32.76±106.29)] or quality of life [IBDQ scores (2.76±41.32)] 
were recorded after completion of the full course of FeS infusions (Table 4). 
 
Table 4 Changes in activity indices of Crohn's disease patients on combined I.V. iron sucrose and infliximab 
treatment 
Infliximab groups CDAI prea CDAI post CDAI change IBDQ preb IBDQ post IBDQ change 
IFX-systematic  
(n = 42) 
213.31 ± 5.95 184.42 ± 91.31 -47.84 ± 121.22 161.39 ± 44.15 164.04 ± 30.84 5.33 ± 47.05 
IFX-episodic  
(n = 45) 
193 ± 112.14 166.45 ± 136.38 -29.70 ± 75.91 164.00 ± 28.34 165.36 ± 38.18 -1.38 ± 31.22 
All IFX  
(n = 87) 
205.26 ± 102.11 176.6 ± 111.59 -32.76 ± 106.29 162.41 ± 38.4 164.65 ± 34 2.76 ± 41.32 
Values are expressed as mean±SD. 
a CDAI = Crohn's Disease Activity Index, Pre = previous to I.V. iron sucrose treatment, post = post to I.V. iron sucrose treatment, change = 
(post-pre) value. 
b IBDQ= Inflammatory Bowel Disease Questionnaire. 
 
4. Discussion 
The results of this study indicate that IFX and FeS work through different mechanisms on haematopoiesis. We 
demonstrate that patients with IBD and anaemia have functional iron deficiency rather than anaemia of chronic 
disease. Restoration of the inflammatory process with IFX even increases the need for rapidly accessible iron 
stores, which is alleviated by replenishing the stores with IV iron. Furthermore, although the safety of FeS in 
IBD had been demonstrated by a limited number of studies from referral IBD centers,5,23-27 our study confirms 
the safety of FeS and adds the experience with combined FeS and IFX treatment in anaemic IBD patients. The 
differential effects of combined IFX and FeS treatment in these haematopoiesis related indices such as EPO and 
sTFR may be implemented to further advance the management of IDRA in patients with IBD. 
First, we confirmed that patients with CD and IDRA have higher than expected endogenous EPO levels 
indicating that EPO increase is strongly related to CD anaemia and that our patients were resistant to endogenous 
EPO production. It is possible that failure of bone marrow to respond to increased EPO levels leads to further 
incremental EPO production. Interestingly, serum EPO levels have been reported to depend not only on the Hb 
concentration but also on the pro-liferative activity of red blood cells and on bone marrow responsiveness.28-30 
Azathioprine use has been related to an increased endogenous EPO production in renal transplant recipients31,32 
probably as a compensatory phenomenon to bone marrow suppression and ineffective erythropoiesis.33-35 
Normalization for the effect of azathioprine in our study was not possible since the vast majority of our patients 
were treated with azathioprine. 
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Secondly, we demonstrated that IFX significantly increases serum EPO, sTFR and VEGF levels. Circumstantial 
evidence suggests that increased local TNF-α production in the bone marrow microenvironment may be 
implicated in the pathogenesis of anaemia of chronic disease.36 In fact, animals treated with TNF-α develop 
anaemia with anaemia of chronic disease characteristics and one could argue that anti-TNFa treatment should 
resolve anaemia of chronic disease.37 Although there is a single report on a patient with CD associated anaemia 
refractory to conventional treatment, which resolved with the administration of IFX38 and a report of two 
myelodysplastic syndrome patients in whom IFX administration resulted in sustained erythroid responses39 we 
believe that our study strongly implicates that IFX per se does not increase haemoglobin levels in CD patients 
but by restoring haematopoiesis IFX even increases functional iron deficiency resulting in an increased demand 
for appropriate iron substitution. 
During this 12-week kinetic study, FeS following IFX treatment restored functional iron deficiency as reflected 
by the decrease of serum EPO and sTFR levels,  thus indicating that IFX and FeS impact IDRA through two 
different pathways. The sTFR kinetics significantly correlated with changes in haemoglobin, thus immediately 
reflecting the efficacy of combined IFX and FeS administration. All these data taken together indicate that the 
relative change in sTFR levels compared to the relative change in EPO levels represents a more sensitive marker 
of the efficacy of FeS therapy than Hb levels. 
The significantly higher increase of EPO in males compared to females after IFX administration and the more 
pronounced relative change of EPO after FeS administration in females points towards the hypothesis that CD 
related anaemia in males is more related to chronic disease while in females iron deficiency remains the 
predominant cause. However, this hypothesis has to be further confirmed. 
Finally, in both transgenic mouse and primate models an inhibitory effect of endogenous VEGF on EPO 
production has been suggested.40 However, in this study we did not observe such a correlation between EPO and 
VEGF levels. 
To the best of our knowledge, this is the first study in IBD anaemic patients demonstrating that FeS and IFX can 
be successfully administered in combination with good tolerance, efficacy and overall safety. Our cohort was 
composed of a rather 'difficult to treat group', mainly consisting of young women with refractory disease in need 
of infliximab therapy. In fact, women older than 50 years of age significantly decrease their iron store deficit due 
to menopause. In previous clinical studies with anaemic IBD patients, FeS infusions have been given using 200 
mg FeS 3 times per week.24 In our study a more 'naturalistic' approach was followed and FeS infusions were 
scheduled with variable intervals to accommodate the predominantly active professionals in our cohort. For 
patients combined infliximab and IV iron infusions sessions limit the burden of the therapy on their activities of 
daily live. 
Only 2/87 patients experienced an infusion related adverse event, which was easily managed. Side effects from 
FeS have been occasionally reported. According to a large post-marketing study the incidence of anaphylactic 
reactions may be as low as 2/100,000 infusions.3 We did not observe any anaphylactic reaction in this cohort and 
in general, tolerability was excellent. The side effects observed in two patients with immediate reactions may 
have been caused by the toxic effect of excess iron released by unstable iron complexes.41 In the additional 
patient a delayed reaction to IFX or a respiratory infection was a more likely cause. Interestingly all three 
patients were on episodic IFX treatment. Systemic reactions to free iron appear to be related to the dose and 
rapidity of administration. The maximal recommended dosage of FeS is 600 mg/week or 7 mg/kg and the 
maximum infusion rate is 20 mg/min.6 Those upper limits were not exceeded in any of our patients. 
A test dose was applied prior to the first infusion following guidelines of iron sucrose administration, although it 
has been suggested that FeS may be safely administered without a prior test dose.42 Although a test dose does not 
exclude adverse reactions we strongly believe as others43 that a history of drug allergy and low body mass44 are 
significant predictors of adverse reactions to IV FeS. In these patients, dose and infusion speed should be 
adjusted to avoid free iron toxicity given that there is no study on the possible impact of IFX on the 
pharmacokinetics of FeS in patients. Interestingly, all of our patients with an adverse reaction had a body weight 
lower than 55 kg. 
High serum iron levels are generally believed to increase oxidative stress and may be pro-inflammatory. A recent 
prospective study enrolling 19 CD patients with iron deficiency anaemia demonstrated that oral ferrous fumarate 
but not intravenous FeS, increased clinical disease activity in IBD patients.26 In this study no significant changes 
in the IBDQ score were observed before and after the completion of FeS infusions and, if anything, a decrease in 
CDAI during FeS infusions was found. The absence of a pro-inflammatory effect is further supported by the 
CRP trends in the study; Mean CRP levels were not increased after FeS treatment and only a quarter of our 
patients had de novo CRP increase during FeS infusions. In contrast to a recent study45 showing a significant 
CDAI improvement 6 weeks after oral iron sulphate or FeS treatment, in our cohort the decrease in CDAI did 
not reach statistical significance probably due to the fact that a great proportion of our patients were already in 
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remission before starting FeS infusions. 
An association between prolonged use of I.V iron and excess incidence of neoplasia, infection and cardiac 
disease has been suggested.46 We recorded only one case of a probable lower respiratory tract infection. Long-
term follow up studies need to be designed in order to assess the real additional risk for cardiac disease and 
extra-intestinal infections in IBD patients frequently receiving FeS infusions combined with any other kind of 
treatment.47-51 
To conclude, IFX and FeS combined treatment can be successively administered with excellent tolerability in 
IBD patients. The kinetic study on haematopoietic parameters in anaemic patients with Crohn's disease showed 
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